FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Global approvals · expansion Exports its filler to 32 countries and is entering new markets such as Taiwan.

  • Report on Taiwanese approval and a local distribution deal for its filler Facetem. Source

Roles often seen at this stageSales & marketing · Regulatory affairs · Device R&D & support

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

CGBio

A maker of regenerative medical devices such as fillers, bone graft substitutes, wound dressings and haemostats, exporting its filler to 32 countries.

Facetem

Marketed

Aesthetic filler exported to 32 countries and approved in Taiwan.

Announced

Said it signed KRW 5.3 billion in supply agreements with partners in five countries at a trade show.

Completion reported

Its filler Facetem received Taiwanese medical-device approval and is starting local distribution.

Official role guide

CGBio careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 시지바이오 "KIMES서 5개국 기업과 53억원 계약체결" ↗네이트 뉴스 · Published 2026-03-29 · Sources checked 2026-11-15 · Original unavailable
  2. 시지바이오, 필러 '페이스템'으로 대만 시장 진출 ↗비즈워치 · Published 2026-10-13 · Sources checked 2026-11-15 · Original unavailable